Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 55

1.

Measurement of neutralizing antibody responses against H5N1 clades in immunized mice and ferrets using pseudotypes expressing influenza hemagglutinin and neuraminidase.

Tsai C, Caillet C, Hu H, Zhou F, Ding H, Zhang G, Zhou B, Wang S, Lu S, Buchy P, Deubel V, Vogel FR, Zhou P.

Vaccine. 2009 Nov 12;27(48):6777-90. doi: 10.1016/j.vaccine.2009.08.056. Epub 2009 Sep 2.

PMID:
19732860
2.
3.

The antigenic architecture of the hemagglutinin of influenza H5N1 viruses.

Velkov T, Ong C, Baker MA, Kim H, Li J, Nation RL, Huang JX, Cooper MA, Rockman S.

Mol Immunol. 2013 Dec;56(4):705-19. doi: 10.1016/j.molimm.2013.07.010. Epub 2013 Aug 7. Review.

PMID:
23933511
4.

One step closer to universal influenza epitopes.

Li OT, Poon LL.

Expert Rev Anti Infect Ther. 2009 Aug;7(6):687-90. doi: 10.1586/eri.09.48. Review.

PMID:
19681695
5.

Molecular anatomy of 2009 influenza virus A (H1N1).

Arias CF, Escalera-Zamudio M, Soto-Del Río Mde L, Cobián-Güemes AG, Isa P, López S.

Arch Med Res. 2009 Nov;40(8):643-54. doi: 10.1016/j.arcmed.2009.10.007. Review.

PMID:
20304251
6.

Changing perspective on immunization against influenza.

Johansson BE, Brett IC.

Vaccine. 2007 Apr 20;25(16):3062-5. Epub 2007 Jan 19. Review.

PMID:
17276554
7.

Haemagglutination-inhibiting antibody to influenza virus.

de Jong JC, Palache AM, Beyer WE, Rimmelzwaan GF, Boon AC, Osterhaus AD.

Dev Biol (Basel). 2003;115:63-73. Review.

PMID:
15088777
8.
9.

Use of animal models to understand the pandemic potential of highly pathogenic avian influenza viruses.

Belser JA, Szretter KJ, Katz JM, Tumpey TM.

Adv Virus Res. 2009;73:55-97. doi: 10.1016/S0065-3527(09)73002-7. Review.

PMID:
19695381
10.
11.

Influenza virus-like particle vaccines.

Haynes JR.

Expert Rev Vaccines. 2009 Apr;8(4):435-45. doi: 10.1586/erv.09.8. Review.

PMID:
19348559
12.

Animal models in influenza vaccine testing.

van der Laan JW, Herberts C, Lambkin-Williams R, Boyers A, Mann AJ, Oxford J.

Expert Rev Vaccines. 2008 Aug;7(6):783-93. doi: 10.1586/14760584.7.6.783. Review.

PMID:
18665776
13.

Serologic assays for influenza surveillance, diagnosis and vaccine evaluation.

Katz JM, Hancock K, Xu X.

Expert Rev Anti Infect Ther. 2011 Jun;9(6):669-83. doi: 10.1586/eri.11.51. Review.

PMID:
21692672
14.

Broadly neutralizing antibodies against influenza viruses.

Laursen NS, Wilson IA.

Antiviral Res. 2013 Jun;98(3):476-83. doi: 10.1016/j.antiviral.2013.03.021. Epub 2013 Apr 9. Review.

15.

Correlates of protection: novel generations of influenza vaccines.

Rimmelzwaan GF, McElhaney JE.

Vaccine. 2008 Sep 12;26 Suppl 4:D41-4. Review.

PMID:
19230158
16.

Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data.

Leroux-Roels G.

Expert Opin Biol Ther. 2009 Aug;9(8):1057-71. doi: 10.1517/14712590903066695. Review.

PMID:
19555313
17.

Functional balance between haemagglutinin and neuraminidase in influenza virus infections.

Wagner R, Matrosovich M, Klenk HD.

Rev Med Virol. 2002 May-Jun;12(3):159-66. Review.

PMID:
11987141
18.

Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara.

Rimmelzwaan GF, Sutter G.

Expert Rev Vaccines. 2009 Apr;8(4):447-54. doi: 10.1586/erv.09.4. Review.

PMID:
19348560
19.

Pseudotype-based neutralization assays for influenza: a systematic analysis.

Carnell GW, Ferrara F, Grehan K, Thompson CP, Temperton NJ.

Front Immunol. 2015 Apr 29;6:161. doi: 10.3389/fimmu.2015.00161. eCollection 2015. Review.

20.

Immune responses to infection with H5N1 influenza virus.

Rimmelzwaan GF, Katz JM.

Virus Res. 2013 Dec 5;178(1):44-52. doi: 10.1016/j.virusres.2013.05.011. Epub 2013 Jun 2. Review.

PMID:
23735534

Supplemental Content

Support Center